Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA reduced its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 5.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 483,399 shares of the specialty pharmaceutical company’s stock after selling 25,526 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Supernus Pharmaceuticals were worth $24,760,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in SUPN. Rubric Capital Management LP purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at about $21,908,000. Woodline Partners LP grew its stake in Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after buying an additional 490,835 shares during the period. Bank of America Corp DE increased its holdings in Supernus Pharmaceuticals by 67.1% in the 3rd quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock valued at $40,282,000 after purchasing an additional 338,584 shares in the last quarter. UBS Group AG grew its stake in shares of Supernus Pharmaceuticals by 137.6% in the third quarter. UBS Group AG now owns 540,123 shares of the specialty pharmaceutical company’s stock valued at $25,812,000 after buying an additional 312,775 shares in the last quarter. Finally, Sofinnova Investments Inc. grew its position in Supernus Pharmaceuticals by 53.5% in the second quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company’s stock valued at $25,192,000 after acquiring an additional 278,575 shares in the last quarter.

Wall Street Analysts Forecast Growth

SUPN has been the subject of several recent analyst reports. Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Sunday, March 8th. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Finally, Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $62.17.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock opened at $48.00 on Friday. The business’s fifty day moving average is $51.14 and its 200-day moving average is $49.89. The stock has a market cap of $2.76 billion, a PE ratio of -70.59, a price-to-earnings-growth ratio of 0.95 and a beta of 0.73. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $59.68.

Insider Buying and Selling

In related news, Director Georges Gemayel sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $53.71, for a total value of $537,100.00. Following the sale, the director directly owned 28,159 shares in the company, valued at $1,512,419.89. The trade was a 26.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jack A. Khattar sold 35,000 shares of the company’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $50.37, for a total value of $1,762,950.00. Following the completion of the transaction, the chief executive officer directly owned 958,100 shares in the company, valued at $48,259,497. This represents a 3.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 120,881 shares of company stock worth $6,139,356. 8.80% of the stock is owned by insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.